Preeclampsia is associated with diastolic dysfunction, peripartum cardiomyopathy, and both pre-existing and subsequent maternal cardiovascular disease. Gene mutations causing idiopathic cardiomyopathy were recently implicated in peripartum cardiomyopathy. We sought to determine whether cardiomyopathy gene mutations are also a contributory factor in preeclampsia.
P
reeclampsia confers both immediate and longterm cardiovascular risk to mothers and their offspring, with significant impact on maternal-child health in the United States and globally. [1] [2] [3] [4] There is a genetic contribution to preeclampsia, 5, 6 and maternal genetic factors are estimated to account for at least 35% of the variance in preeclampsia risk. 7 Cardiovascular disease (CVD), which is now known to be associated with preeclampsia, remains the leading cause of death globally for both men and women, 8 but the epidemiology and pathophysiology of CVD differ by sex. [9] [10] [11] After a pregnancy complicated by preeclampsia, women have an increased risk of CVD and cardiovascular-related mortality, as much as 8-fold higher after preterm preeclampsia compared with women with all normal pregnancies. 12, 13 In 2011, the American Heart Association formally recognized preeclampsia as a clinically important risk factor for CVD in women. 10 The association between preeclampsia and CVD probably reflects both shared risk factors and conferrence of cardiovascular risk during preeclampsia pregnancy.
14 Preeclampsia is associated with diastolic dysfunction, [15] [16] [17] [18] peripartum cardiomyopathy, 19 and later-life cardiomyopathy. 20 Asymptomatic diastolic dysfunction and heart failure with preserved ejection fraction are common in women and associated with increased cardiovascular morbidity and mortality. 21 The general limitations of classic genome-wide association studies have become increasingly clear, 22 and genome-wide association study findings in the field of preeclampsia have been inconsistent. 23 By design, genome-wide association studies only detect mutations that arose thousands of years ago, and these mutations usually have modest effects. High-impact mutations associated with preeclampsia and cardiomyopathy are likely to have relatively low frequencies in the population because of negative selection. Identification of rare variants associated with preeclampsia and cardiomyopathy may provide insights into the clinical heterogeneity and pathophysiologic processes of both disorders. A recent study of idiopathic peripartum cardiomyopathy evaluated rare gene variants previously associated with idiopathic and heritable dilated cardiomyopathies. This study reported shared genetic associations between peripartum cardiomyopathy and idiopathic cardiomyopathy unrelated to pregnancy. Variants in 1 gene, TTN, which encodes the sarcomeric protein titin, were particularly common. In addition, in peripartum cardiomyopathy, some TTN variants were specifically associated with impaired cardiac function in the year postpartum. 24 An improved understanding of the relationship between preeclampsia and cardiac disease has the potential to influence pregnancy care and postreproductive care and improve cardiovascular health for women. We asked whether cardiomyopathy-related rare gene variants might be overrepresented in preeclampsia, potentially contributing to the association of preeclampsia with diastolic dysfunction and, in a smaller subset of women, to cardiomyopathy. Here, we sought to determine whether rare gene variants associated with idiopathic and peripartum cardiomyopathy are also associated with preeclampsia.
METHODS
The data, analytic methods, and study materials will be made available through The Preeclampsia Registry (TPR) 25 to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population
Study protocols regarding human subjects were approved by the Chesapeake Institutional Review Board. All subjects provided written informed consent via an online enrollment process. Cases were participants in TPR and Biobank 25 with a history of at least 1 previous pregnancy confirmed to be complicated by preeclampsia based on current diagnostic criteria established by the American College of Obstetricians and Gynecologists. 26 Women enrolled in TPR self-reported their demographic and clinical information, including detailed obstetric history, through an online questionnaire. TPR participants who reported a history of preeclampsia within the past 7 years and reported no previous prepregnancy pre-existing medical condition (defined as hypertension, kidney or liver
Clinical Perspective
What Is New?
• The pregnancy disorder preeclampsia is associated with an increased risk of subsequent cardiovascular disease in women, and it is unknown to what extent this association reflects shared risk factors, including genetic contributors.
• This study demonstrates that gene variants known to be associated with idiopathic and peripartum cardiomyopathy are also associated with preeclampsia.
• These results underscore the need for further investigation into possible shared pathophysiology and differentiation of phenotypic subtypes of preeclampsia, with implications for postreproductive health in women.
What Are the Clinical Implications?
• Evaluation of gene variants in cardiomyopathyrelated genes may help to identify women with particularly high risk of future cardiac disease after preeclampsia.
• These findings support the need for future prospective studies to confirm our findings and evaluate clinical strategies for risk stratification during and after pregnancy. Figure 1 . A cohort of local controls matched for race (n=530) was sequenced using the same protocols and instruments as part of an unrelated study of endometriosis genetics (Endometriosis Cohort, or EndoC). The subjects in the EndoC cohort consented to have their deidentified sequence data used in other studies concerning women's health. The European ethnicity of EndoC participants was confirmed using admixture analysis from our previously published genome-wide association study. 27 Comparison was also made with published rare variant data taken from ExAC (Exome Aggregation Consortium), a project that aggregated and harmonized sequencing data from 60 706 unrelated individuals. Our analysis specifically included 33 000 participants with European, non-Finnish ancestry.
Samples and DNA Extraction
Saliva samples were collected using the Oragene 300 saliva collection kit (DNA Genotek, Ottawa, Ontario, Canada), and DNA was extracted using an automated extraction instrument, AutoPure LS (QIAGEN, Valencia, CA), and the manufacturer's reagents and protocols. DNA quality was evaluated by calculation absorbance ratio Optical Density 260 /Optical Density 280 , and DNA quantification was measured using PicoGreen (Life Technologies, Grand Island, NY).
Exome Sequencing and Variant Discovery
Whole exome sequencing (WES) was performed on the preeclampsia cohort using an Ion Proton Instrument as per the manufacturer's protocol (Life Technologies, Carlsbad, CA) using their AmpliSeq Exome Capture Kit. Sequence alignment and variant calling were performed against the reference human genome (University of California Santa Cruz hg19 version). The variant discovery was performed using the Life Technologies Texas Medication Algorithm Project algorithm with their default parameter settings, and the Life Technologies Torrent Variant Caller was used to discover variants. The variants identified from the Torrent Variant Caller were taken further for downstream analysis. The variants included were single nucleotide variants, short insertions, or deletions.
Exclusion Process
Variant annotation was performed using ANNOVAR. 28 The analysis was conducted on rare (minor allele frequency <0.1%) mutations in the 43 cardiomyopathy-related genes. 24 The list of all 43 cardiomyopathy-related genes is shown in Table I in the online-only Data Supplement. The coding variants were classified as missense, frame-shift, splicing, stopgain, or stop-loss. Variants were considered loss-of-function if they caused a stop-gain, splicing, or frame-shift insertion or deletion. Prediction of protein function was evaluated in silico using 7 different algorithms (Polyphen 2, 29 Sift, 30 Mutation Accessor, 31 Mutation Taster, 32 FATHMM, 33 LRT, 34 and MetaLR 35 ). Missense variants were deemed damaging missense if they were predicted to be damaging by at least 1 of the 7 algorithms tested. The genes that harbor these variants were also checked against the published frequently mutated genes ("FLAGS") gene list to understand whether the gene is frequently mutated in humans. 36 
Statistical Analysis
A binomial test was used to compare frequencies of lossof-function and damaging missense variants between the preeclampsia cohorts and the population data from 2 unrelated control populations: (1) n=530 unrelated endometriosis controls (EndoC) sequenced at the same laboratory, and (2) n=33 000 individuals with European ancestry from ExAC. Preeclampsia was not excluded from the population controls, biasing against association. Although the prevalence of preeclampsia was not available for ExAC or EndoC, preeclampsia occurs in ≈3% to 6% of pregnancies overall. 37 Within the preeclampsia population, clinical characteristics of subjects with and without an identified variant were compared using the Fisher exact test for categorical variables and Mann-Whitney U test for continuous variables. Analyses were performed in R Statistical Package or Stata, version 14.2.
RESULTS
A total of 181 women with preeclampsia were included in this study. Clinical and demographic characteristics are shown in Table 1 . Approximately 72% of the cases had ≥1 preterm preeclampsia delivery <37 
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weeks. Ninety-six percent of the 181 women are selfreported to be of European ancestry. The WES summary for all 181 preeclampsia subjects is shown in Table I in the online-only Data Supplement. On average, 95% of the bases sequenced were covered at a read depth of at least ×20. The average sequencing depth for all preeclampsia cohort participants was ×106. We detected approximately ≈20 000 variants per preeclampsia individual in the coding regions. We restricted our analysis to rare (minor allele frequency <0.1%) damaging missense and loss-of-function variants in the 43 cardiomyopathy-related genes as shown in Table I in the online-only Data Supplement. Among the 181 women with preeclampsia, WES identified 10 rare truncating variants within the 43 cardiomyopathy-related genes considered. Two were splicing, 2 of them stop-gain, and the remaining 6 were frame-shift insertion. Results are summarized in Table 2 . The overall prevalence of these loss-offunction variants in the preeclampsia cohort (5.5%) ‡Subjects with a damaging missense variant were compared with those with no variant. §Denominators varied slightly for each factor because of missing data and are indicated for each categorical variable. #Categorical data compared with Fisher exact test. ‖Continuous data compared with Mann-Whitney. **Prepregnancy BMI data available for 174/181 subjects in the overall population, 93/98 subjects without a cardiomyopathy-related variant, 9/9 subjects with a loss-of-function variant, and 78/80 subjects with a damaging missense variant.
† †For multiple gestations (all twins), results were analyzed for the first twin. ‡ ‡Birthweight less than 10th percentile for gestational age and fetal sex based on Shihab et al. 33 § §Blood pressure data (maximum systolic and diastolic blood pressure) available for 174/181 subjects in overall population, 94/98 subjects without a cardiomyopathy-related variant, 8/9 subjects with a loss-of-function variant, and 77/80 subjects with a damaging missense variant. 8E-4) . In the preeclampsia cohort, 90% of loss-of-function variants in the 43 cardiomyopathy-related genes were identified in TTN, compared with 15% in EndoC (P=3.2E-7) and 10% in ExAC (P=9.1E-9). Eight individuals had variants in a heterozygous form whereas 1 individual was noted to be an apparent homozygote. Further analysis of this subject's sequencing data suggests that this subject is hemizygous-carrying both a coding variant and a deletion, suggested by a 300-kb run of homozygosity around the "homozygous" rare variant (extending between nucleotides 179325735 and 179644855). This deletion was not detected at the resolution of Cytoscan HD microarray test (Affymetrix, Santa Clara, CA).
Circulation
Among the 181 women with preeclampsia, WES demonstrated 228 rare damaging missense variants within the 43 cardiomyopathy-related genes considered (Table III in the online-only Data Supplement). These damaging missense variants were distributed among 80 of the preeclampsia subjects (Table 1 ). In the preeclampsia cohort, the prevalence of TTN gene-related rare damaging missense variants was 67.9%, compared with 47.2% in EndoC (P=2.28E-8) and 49.9% in ExAC (P=1.07E-6). The majority of the damaging missense variants (61%) were clustered in the I band of TTN gene (Figure 2) . In peripartum and idiopathic dilated cardiomyopathy, identified mutations tend to be more common in the A band. 24, 38 In the preeclampsia cohort, the prevalence of rare damaging missense/loss-of-function variants in the TTN gene was 73%, compared with 48% in EndoC (P=1.36E-11) and 51% in ExAC (P=2.4E-9). However, the proportion of preeclampsia women (46%) with any damaging missense/loss-of-function variant in the TTN gene was just slightly higher than the EndoC cohort (37%, P=0.01), implying a higher number of mutations per person in the TTN gene in women with preeclampsia. In fact, the presence of ≥2 rare damaging missense/loss-of-function mutations in TTN gene was observed in excess in women with preeclampsia compared with the EndoC cohort (16% versus 9.3%, P=0.0043). In the preeclampsia cohort, 6 subjects had 3 variants in TTN, 2 subjects had 4 variants, 1 subject had 6 variants, and an additional subject carried 8 TTN variants. A comparison of mutation burden on individual level with ExAC was not possible because ExAC does not provide individual data.
Clinical Characteristics
The clinical and demographic characteristics of all preeclampsia subjects according to variant status are summarized in Table 1 . Subjects with and without loss- Figure 2. Distribution of rare damaging/truncating mutations in preeclampsia subjects along the protein structure of TTN. The green colored dots represent damaging missense mutations, and the black dots show truncating mutations. The distinct bands of TTN gene are depicted below the protein schematic, based on data from Schwarz et al. 32 The mutations in preeclampsia subjects are predominantly clustered in the I-Band of TTN.
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of-function or damaging missense variants in cardiomyopathy-related genes had similar characteristics in their first preeclampsia pregnancy in terms of maternal age, parity, multiple gestation, cesarean delivery, fetal sex, and smoking. Subjects with a loss-of-function variant were less likely to have had ≥1 preterm preeclampsia deliveries overall (44% versus 78%, P=0.04, compared with subjects with no variant). In the first preeclampsia pregnancy, subjects with a loss-of-function or a damaging missense variant had lower maximum systolic blood pressure compared with those without a variant. Gestational age at delivery was also higher for those with a damaging missense variant. Of note, though birth weight was also higher in the variant group, this was driven by later gestational age, as the prevalence of birth weight below the 10th percentile 39 was similar across groups.
TPR asks participants to provide updated information about their health on an approximately annual basis. For this study, 131/181 (72%) provided ≥1 update. The timing of update provisions by participants varied by participant and was on average 4.0±3.4 years after last delivery and 5.3±3.7 years after last preeclampsia delivery. Of the 131 respondents, 1 (0.8%) reported incident heart disease, specifically development of a new arrhythmia. This subject carried a damaging missense variant in 1 of the cardiomyopathy-related genes. Fourteen (10.7%) reported hypertension; of these, 6 (43%) had a damaging missense variant and 1 (7%) had both a damaging missense variant and a loss-of-function variant. Eighteen (13.7%) reported hypercholesterolemia; of these, 4 (22%) had a damaging missense variant and 1 (6%) had both a damaging missense variant and a loss-of-function variant.
DISCUSSION
Women with a history of preeclampsia were more likely than reference populations to carry protein-altering mutations in genes associated with idiopathic or peripartum cardiomyopathy. Variants were most commonly found in the TTN gene, which encodes the sarcomeric protein titin. Notably, preeclampsia subjects had a greater number of TTN variants per person than reference populations. Though the implications of multiple TTN mutations on preeclampsia pathophysiology are not specifically known, the field of cardiovascular genetics has come to appreciate the importance of multiple gene mutations on individuals' cardiovascular risk and disease severity. 40 Our findings can inform future studies aiming to define and predict both preeclampsia directly and associated later-life CVD. Shared genetic risk factors for preeclampsia and cardiomyopathy could ultimately provide insight into pathophysiology, defining clinical phenotypes within these clinically heterogeneous conditions, and predicting long-term risk.
Preeclampsia-associated mutations clustered in the I-band of TTN, which encodes the elastic part of the titin molecule and has implications for cardiac muscle elasticity and generation of passive tension during diastole. 41, 42 Although the literature is limited with regard to the functional consequences of I-band variants specifically, there is evidence that the distribution of mutations differs between conditions, including, for example, dilated cardiomyopathy versus hypertrophic cardiomyopathy. 43 Of women with preeclampsia, those with a variant in a cardiomyopathy-related gene were less likely to have had a preterm preeclampsia delivery than those without a variant. In addition, clinically modest but statistically significant differences in characteristics of subjects' first preeclampsia pregnancy suggested that the phenotype of preeclampsia in those with a variant would be considered mild preeclampsia by traditional obstetric criteria. 26 This suggests that the association of cardiomyopathy-related genetic variants with preeclampsia may have the potential to identify a subgroup at risk for subsequent cardiac dysfunction not discernable by acute clinical obstetric presentation. Published studies 13, 44 demonstrate that associations of preeclampsia with subsequent CVD are strongest in early-onset preeclampsia and preeclampsia with severe features, with odds ratios of approximately 8. However, late-onset preeclampsia without severe features is also associated with subsequent CVD, approximately 2-fold higher; further risk stratification of this group would be beneficial for targeting follow-up and potential interventions. As such, our findings highlight a possible future role for genetic testing to facilitate identification of women at particularly high risk for CVD after preeclampsia, above and beyond obstetric phenotypes, and underscore the need for additional studies. It is important to note that further investigation, ideally including longitudinal, long-term follow-up, would be necessary to discern clinically significant phenotypic differences after preeclampsia, according to variant status.
This study represents the largest published set of WES data on preeclampsia to date. The analysis presented here focused on a set of genes known to be associated with cardiomyopathy to begin to explore epidemiological and pathophysiologic connections between preeclampsia and related CVD. Additional strengths of this study include detailed phenotypic information from preeclampsia subjects, including medical records review. The large number of subjects in the population allowed for strict characterization of clinical characteristics to minimize heterogeneity.
Mutations in the TTN gene should be interpreted with caution, as TTN is one of the most frequently mutated genes in the human genome. However, the higher mutation burden per subject seen in preeclampsia, as well as the predicted functional significance of the detected TTN variants, support functional implications of the TTN variants detected. It is also important to note that preeclampsia was not excluded from reference populations used for comparison in this study; this may have led to an underestimation of differences between the preeclampsia cohort and comparison populations. A potential limitation of our study is that subjects self-identified with preeclampsia through enrollment in TPR. Medical records were obtained and systematically reviewed, confirming diagnoses in all included cases. Self-reporting might have resulted in a hidden ascertainment bias (ie, a greater percentage of women with findings after the acute presentation during late pregnancy). The TPR population is enriched for severe phenotypes of preeclampsia, as well as higher education and online literacy, than the general population. Interestingly, despite this, we found that preeclampsia subjects with a cardiomyopathy-related genetic variant tended to have a later onset of preeclampsia.
The extent to which a cardiomyopathy-related gene variant may be predictive of heart failure in women with preeclampsia is unknown, and additional shared risk factors (eg, obesity, diabetes mellitus, and chronic hypertension) are likely to modulate outcomes. Environmental exposures differ between preeclampsia, peripartum cardiomyopathy, and idiopathic cardiomyopathy, with pregnancy-related exposures to factors such as soluble fms-like tyrosine kinase-1 and cleavage fragments of prolactin unique to preeclampsia and peripartum cardiomyopathy. These types of pregnancyspecific exposures may contribute to the earlier onset of disease development in peripartum cardiomyopathy versus idiopathic cardiomyopathy in women with TTN variants. 24 It is also important to note that the prevalence of loss-of-function variants specifically was similar between the preeclampsia cohort and the ExAC cohort; this may be in part attributable to enrichment in ExAC for participants with high cardiovascular risk. Interestingly, peripartum cardiomyopathy was associated with a higher overall prevalence of loss-of-function variants than ExAC (15%), 24 whereas the preeclampsia cohort showed a particularly high prevalence of loss-of-function variants in TTN. Although preeclampsia is associated with cardiac dysfunction, especially diastolic dysfunction, it is phenotypically distinct from peripartum cardiomyopathy, and factors such as mutation burden may play a more important role in preeclampsia versus absolute prevalence of genetic variants related to cardiomyopathy as seen in peripartum cardiomyopathy.
Overall, we conclude that genetic changes predisposing to idiopathic and postpartum cardiomyopathy are also associated with preeclampsia. These genetic variations, including assessment of mutation burden, may have a role in identifying women at risk for postpreeclampsia CVD, beyond established obstetric phenotypes. Further studies, including replication in an additional cohort, are needed.
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